Litcius/Paper detail

CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression

Haojie Chen, Keqin Dong, Jie Ding, Jia Xia, Fajun Qu, Fuying Lan, Haihong Liao, Yuhang Qian, Jiacheng Huang, Zihan Xu, Zhengqin Gu, Bowen Shi, Mingming Yu, Xingang Cui, Yongjiang Yu

2024Cancer Letters16 citationsDOI

Topics & Concepts

Prostate cancerEnzalutamideCRISPRCancer researchPAK1Drug resistanceBiologyCancerMedicineGeneInternal medicineOncologyBioinformaticsSignal transductionAndrogen receptorGeneticsProstate Cancer Treatment and ResearchPARP inhibition in cancer therapyGenetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression | Litcius